The approval, announced by Irvine-based Allergan Aesthetics, an AbbVie company, expands the product's clinical application beyond its previous use for cheek smoothness. Clinical data submitted for the authorization showed that nearly 75% of study participants achieved significant improvement in neck line appearance after one month. A majority of those patients maintained those results through the six-month mark.

The treatment is minimally invasive and incorporates lidocaine to mitigate discomfort during the procedure. While the results are promising, the FDA has mandated a specific training program for medical providers before they are permitted to purchase or administer the product. Allergan expects the treatment to be available commercially later this year. Patients should note that common side effects, including redness, bruising, and tenderness at the injection site, typically resolve within two weeks.